About this trial
The study will employ a combined laboratory-ambulatory design. Participants will engage in ambulatory assessment over the course of 14 days, wearing biosensors assessing transdermal alcohol concentration (TAC) and providing breathalyzer readings in real-world contexts. Also during this period, participants will attend three laboratory alcohol-administration sessions scheduled at one-week intervals, with alcohol dose and rate of consumption manipulated within and between participants, respectively. Laboratory visits will also double as ambulatory orientation, check-in, and close-out sessions.
Eligibility criteria
Qualifiers
21 years or older
drink alcohol at least 2x weekly
Disqualifiers
psychological or medical conditions that might contraindicate alcohol-administration
history of adverse reaction to type and amount of beverage used in the study
currently seeking treatment for alcohol use disorder
does not drink alcohol regularly
Trial design
Treatments tested in this trial
- Alcohol
Treatment groups
Sponsors and collaborators
University of Illinois at Urbana-Champaign
Lead sponsor
National Institutes of Health (NIH)
Collaborator